Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 4, 2013, Pages 671-677

  Takeji, Satoru ^a   Hirooka, Masashi ^a   Koizumi, Yohei ^a   Tokumoto, Yoshio ^a   Abe, Masanori ^a   Ikeda, Yoshio ^a   Nadano, Seijin ^b   Hiasa, Yoichi ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

AFP L3; Alpha fetoprotein; DCP; Hepatocellular carcinoma; NX PVKA; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; ANTIBODY; DECARBOXYPROTHROMBIN; P 11 ANTIBODY; P 16 ANTIBODY; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL;

EID: 84875618289     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12076     Document Type: Article

References (33)

1. El-Serag HM, Lenhard RK. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Blanchard RA, Furie BC, Kruger SF, Waneck G, Jorgensen MJ, Furie B. Immunoassays of human prothrombin species which correlate with functional coagulation activities. J. Lab. Clin. Med. 1983; 101: 242-255.
3. Liebman HA, Furie BC, Tong MJ etal. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N. Engl. J. Med. 1984; 310: 1427-1431.
4. Okuda H, Nakanishi T, Takatsu K etal. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999; 85: 812-818.
5. Bajaj SP, Price PA, Russell WA. Decarboxylation of gamma-carboxyglutamic acid residues in human prothrombin. J. Biol. Chem. 1982; 257: 3726-3731.
6. Naraki T, Kohno N, Saito H etal. γ-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-γ-carboxy prothrombin. Biochim. Biophys. Acta 2002; 1586: 287-298.
7. Toyoda H, Kumda T, Osaki Y etal. Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci. 2012; 103: 921-925.
8. Aoyagi Y, Isemura M, Suzuki Y etal. Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet 1985; 326: 1353-1354.
9. Sato Y, Nakata K, Kato Y etal. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N. Engl. J. Med. 1993; 328: 1802-1806.
10. Motohara K, Endo F, Matsuda I. Effect of vitamin K administration on acarboxyprothrombin (PIVKA-II) levels in newborns. Lancet 1985; 326: 242-244.
11. Motohara K, Kuroki Y, Kan HK etal. Detection of vitamin deficiency by use of an enzyme-linked immunosorbent assay for circulating for circulating abnormal prothrombin. Pediatr. Res. 1985; 19: 354-357.
12. Akaike H. A new look at statistical model identification. IEEE Trans. Automat. Control 1974; 19: 716-723.
13. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Cancer 1994; 73: 2464-2469.
14. Hagiwara S, Kudo M, Kawasaki T etal. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J. Gastroenterol. 2006; 41: 1214-1219.
15. Hakamada K, Kimura N, Miura T etal. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J. Gastroenterol. 2008; 14: 1370-1377.
16. Kobayashi M, Ikeda K, Kawamura Y etal. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571-580.
17. Yamashita Y, Tsuijita E, Takeishi K etal. Predictors for microinvasion of small hepatocellular carcinoma <2cm. Ann. Surg. Oncol. 2012; 19: 2027-2034.
18. Bae HM, Lee JH, Yoon JH, Kim YJ, Heo DS, Lee HS. Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. BMC Cancer 2011; 11: 435-445.
19. Inagaki Y, Xu HL, Hasegawa K etal. Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis. J. Dig. Dis. 2011; 12: 481-488.
20. Harrell FE Jr, Lee KL, Califf RM etal. Regression modeling strategies for improved prognostic prediction. Stat. Med. 1984; 3: 143-152.
21. Kobayashi M, Kuroiwa T, Suda T etal. Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha-fetoprotein. Hepatol. Res. 2007; 37: 914-922.
22. Nouso K, Kobayashi Y, Nakamura S etal. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J. Gastroenterol. Hepatol. 2011; 26: 1195-1200.
23. Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N. Clinical and molecular instates into the hepatocellular carcinoma tumour marker des-γ-carboxy prothrombin. Liver Int. 2011; 31: 22-35.
24. Tang W, Miki K, Kokudo N etal. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int. J. Oncol. 2003; 22: 969-975.
25. Uehara S, Gotoh K, Handa H etal. Distribution of the heterogeneity of des-γ-carboxyprothrombin in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2005; 20: 1545-1552.
26. Nakamura T, Nishizawa T, Hagiya M etal. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-443.
27. Suzuki M, Shiraha H, Fujikawa T etal. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J. Biol. Chem. 2005; 280: 6409-6415.
28. Pohl A, Behling C, Oliver D etal. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am. J. Gastroenterol. 2001; 96: 3142-3146.
29. Shah AG, Lydecker A, Murray K etal. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009; 7: 1104-1112.
30. Koike Y, Shiratori Y, Sato S etal. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 2001; 91: 561-569.
31. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-755.
32. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-338.
33. Tateishi R, Yoshiba H, Shiina S etal. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: 419-425.